Radiation Exposure and Safety of Lymphatic Mapping and Selective (Sentinel) Lymph Node Biopsy Procedures for Melanoma and Breast Cancer Treatment

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12605000428662

Acronym

Radiation Safety in Sentinel N

Enrollment

Registered

2005-09-16

Start date

1998-01-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

The aim of the study was to evaluate radiation exposure and safety for staff in the treatment of patients with Early Stage I/II Melanoma and Breast Cancer using Lymphatic Mapping and Selective (Sentinel) Lymph Node Biopsy. This treatment has shown a high degree of safety with very few adverse events. The radiation exposure was studied during surgery and during transport and processing of specimens.

Eligibility

Sex/Gender

All

Age

0 to No maximum

Healthy volunteers

Inclusion criteria

Stage I and II cutaneous melanoma > 1mm in Breslow thickness or > Clark Level III; Stage I and II Breast Cancer; Absence of Metastases; Informed Consent.

Exclusion criteria

Pregnancy; Other malignancy.

Outcome results